Dyax signs distribution contract with taiba for Kalbitor in Middle East
Taiba expects to launch Kalbitor in 2012. The profits on Kalbitor sales within the licensed territory will be shared by Dyax and taiba. Dyax president and chief executive
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
The company manufactures a recombinant mammalian cell produced third-generation Sci-B-Vac in its biologics manufacturing facility in Rehovot, Israel. The multiple clinical studies conducted on Sci-B-Vac have demonstrated that